On December 12, 2019 Toronto Innovation Acceleration Partners ("TIAP") reported the launch of a new project developed under the BRIDGE LAB150, a partnership between Evotec SE and TIAP (Press release, Evotec, DEC 12, 2019, View Source;announcements/press-releases/p/toronto-innovation-acceleration-partners-tiap-adds-novel-kras-oncology-project-to-its-lab150-portfolio-5879 [SID1234552313]). The project will be focusing on breakthroughs in novel cellular drug screening systems in oncology-focused scientific KRAS research by Professor Igor Stagljar at the University of Toronto, a TIAP Member, and aims to develop therapeutics targeting the protein-protein interactions of KRAS and its downstream interacting partners.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The low survival rates of three of the four most lethal cancers in North America – pancreatic, colorectal and lung – are associated with KRAS mutations, a well-established cancer driver. Although there is an urgent need for KRAS-targeting therapeutics, so far there has been a lack of clinically available drugs as oncogenic KRAS is very difficult to target directly.

LAB150 accelerates academic research towards commercial outcomes by providing funding and access to pharmaceutically validated platforms and expertise. For further information on the new LAB150 projects